Please ensure Javascript is enabled for purposes of website accessibility

Why Poseida Therapeutics Stock Is Popping Today

By Keith Speights - Feb 24, 2021 at 12:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech reported pipeline progress at its virtual R&D Day.

What happened

Shares of Poseida Therapeutics (NASDAQ:PSTX) were jumping 21.2% higher as of 12:08 p.m. EST on Wednesday. The big gain came with the company providing a pipeline update at its virtual R&D Day today.

So what

Poseida said that its virtual R&D Day will include a presentation of a case study for one patient receiving P-PSMA-101. It's an experimental chimeric antigen T cell receptor (CAR-T) therapy that's currently being evaluated in a phase 1 study targeting prostate cancer. The patient in the case study to be discussed experienced a decrease in prostate-specific antigen levels of more than 50% three weeks after receiving P-PSMA-101.

Test tube rack with increasingly higher levels of green fluid in each test tube and a green line with an arrow sloping upward

Image source: Getty Images.

The company plans to present updated preclinical data for two allogeneic CAR-T candidates, P-BCMA-ALLO1 and P-MIC1C-ALLO1. Allogeneic CAR-T therapies use other individuals' T cells and could be "off-the-shelf" treatments that are cheaper and quicker to use than current CAR-T therapies. In addition, Poseida's presentations include updates for several other preclinical programs and introduced a new potential pipeline candidate.

Clinical-stage biotech stocks rise and fall nearly entirely based on investors' views about their pipeline prospects. Poseida's updates today gave investors a good reason to be increasingly optimistic about its prospects.

Now what

Poseida expects to provide additional updates for several of its programs later this year. It also expects to file for U.S. approval to advance P-MUC1C-ALLO1 into clinical testing as a treatment for several types of solid tumors by the end of 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.